Drug response prediction in high-risk multiple myeloma

被引：9

作者：

Vangsted, A. J. ^{[1
]}

Helm-Petersen, S. ^{[2
]}

Cowland, J. B. ^{[2
,5
]}

Jensen, P. B. ^{[3
]}

Gimsing, P. ^{[1
]}

Barlogie, B. ^{[4
]}

Knudsen, S. ^{[3
]}

机构：

[1] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

[2] Copenhagen Univ Hosp, Granulocyte Res Lab, Copenhagen, Denmark

[3] Med Prognosis Inst, Hematol Oncol, Horsholm, Denmark

[4] Mt Sinai Hosp, New York, NY 10029 USA

[5] Copenhagen Univ Hosp, Dept Clin Genet, Copenhagen, Denmark

来源：

GENE | 2018年 / 644卷

关键词：

Drug response prediction; High-risk; Multiple myeloma; STEM-CELL TRANSPLANTATION; EXPRESSION SIGNATURE; REFRACTORY MYELOMA; WORKING GROUP; BORTEZOMIB; STRATIFICATION; THALIDOMIDE; CONSENSUS; THERAPY; GENES;

D O I：

10.1016/j.gene.2017.10.071

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10 years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR = 2.4 (1.2-4.9, P = 0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P = 0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P = 0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

引用

页码：80 / 86

页数：7

共 31 条

[1] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[2] Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].

Barlogie, Bart ;

Anaissie, Elias ;

van Rhee, Frits ;

Haessler, Jeffrey ;

Hollmig, Klaus ;

Pineda-Roman, Mauricio ;

Cottler-Fox, Michele ;

Mohiuddin, Abid ;

Alsayed, Yazan ;

Tricot, Guido ;

Bolejack, Vanessa ;

Zangari, Maurizio ;

Epstein, Joshua ;

Petty, Nathan ;

Steward, Douglas ;

Jenkins, Bonnie ;

Gurley, Jennifer ;

Sullivan, Ellen ;

Crowley, John ;

Shaughnessy, John D. Jr .

BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185

[3] Curing myeloma at last: defining criteria and providing the evidence [J].

Barlogie, Bart ;

Mitchell, Alan ;

van Rhee, Frits ;

Epstein, Joshua ;

Morgan, Gareth J. ;

Crowley, John .

BLOOD, 2014, 124 (20) :3043-3051

[4] Targets for Ibrutinib Beyond B Cell Malignancies [J].

Berglof, A. ;

Hamasy, A. ;

Meinke, S. ;

Palma, M. ;

Krstic, A. ;

Mansson, R. ;

Kimby, E. ;

Osterborg, A. ;

Smith, C. I. E. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 82 (03) :208-217

[5] Molecular pathogenesis and a consequent classification of multiple myeloma [J].

Bergsagel, PL ;

Kuehl, WM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6333-6338

[6] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[7] Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome [J].

Decaux, Olivier ;

Lode, Laurence ;

Magrangeas, Florence ;

Charbonnel, Catherine ;

Gouraud, Wilfried ;

Jezequel, Pascal ;

Attal, Michel ;

Harousseau, Jean-Luc ;

Moreau, Philippe ;

Bataille, Regis ;

Campion, Loic ;

Avert-Loiseau, Herve ;

Minvielle, Stephane .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4798-4805

[8] Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome [J].

Dickens, Nicholas J. ;

Walker, Brian A. ;

Leone, Paola E. ;

Johnson, David C. ;

Brito, Jose L. ;

Zeisig, Athanasia ;

Jenner, Matthew W. ;

Boyd, Kevin D. ;

Gonzalez, David ;

Gregory, Walter M. ;

Ross, Fiona M. ;

Davies, Faith E. ;

Morgan, Gareth J. .

CLINICAL CANCER RESEARCH, 2010, 16 (06) :1856-1864

[9] Inhibiting MEK in MAPK pathway-activated myeloma [J].

Heuck, C. J. ;

Jethava, Y. ;

Khan, R. ;

van Rhee, F. ;

Zangari, M. ;

Chavan, S. ;

Robbins, K. ;

Miller, S. E. ;

Matin, A. ;

Mohan, M. ;

Ali, S. M. ;

Stephens, P. J. ;

Ross, J. S. ;

Miller, V. A. ;

Davies, F. ;

Barlogie, B. ;

Morgan, G. .

LEUKEMIA, 2016, 30 (04) :976-980

[10] Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma [J].

Heuck, C. J. ;

Qu, P. ;

van Rhee, F. ;

Waheed, S. ;

Usmani, S. Z. ;

Epstein, J. ;

Zhang, Q. ;

Edmondson, R. ;

Hoering, A. ;

Crowley, J. ;

Barlogie, B. .

LEUKEMIA, 2014, 28 (12) :2410-2413

← 1 2 3 4 →